NHS to pay 25% more for innovative drugs after UK–US zero-tariff deal
by Lisa O’Carroll and Denis Campbell from Science | The Guardian on (#71VK3)
Agreement could cost NHS an extra 3bn a year, industry sources estimate
The UK has agreed to pay 25% more for new medicines by 2035 as part of a US-UK drug pricing deal that will cost an estimated additional 3bn a year.
The transatlantic agreement will also see the health service in England, which currently spends 14.4bn a year on innovative therapies, double the percentage of GDP it allocates to buying such products, from 0.3% to 0.6% over the next decade.
Continue reading...